Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cefprozil · 4 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Cefprozil 250 mg/5 ml Oral Suspension (Sandoz, Austria) |
| 2 | ACTIVE_COMPARATOR | Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb, USA) |
| Name | Type | Description |
|---|---|---|
| Cefprozil 250 mg/5 ml Oral Suspension (Sandoz, Austria) | DRUG | - |
| Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb, USA) | DRUG | - |
| Cefprozil 250 mg/5 ml Oral Suspension (Sandoz GmbH) | DRUG | - |
| Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb) | DRUG | - |
| Cefprozil 500 mg Tablets (Sandoz GmbH) | DRUG | - |
| Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb) | DRUG | - |
| Cefprozil 500 mg Tablets (Sandoz, GmbH) | DRUG | - |
| Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb, USA) | DRUG | - |
Inclusion Criteria: * No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. Exclusion Criteria: * Positive test results for HIV or hepatitis B or C. * Treatment for drug or alcohol dependence.
Cefprozil is a small molecule drug developed by Novartis AG (ticker NVS). It has been studied in Phase 1 clinical trials, with four completed trials enrolling a total of 105 participants. The trials were conducted in healthy volunteers and evaluated bioavailability of cefprozil tablets and oral suspension formulations under fed and fasting conditions.
Cefprozil is developed by Novartis AG, which trades under the ticker NVS. The drug has been studied in Phase 1 trials, and the tested formulations include Cefprozil 500 mg tablets and Cefprozil 250 mg/5 ml oral suspension. All four listed trials are completed.
Cefprozil is in Phase 1 clinical development. Four Phase 1 trials have been completed, with no active trials currently listed. The completed studies enrolled 105 participants total and were conducted in healthy volunteers. The trials were randomized and active controlled, though not double blind.
Cefprozil has been evaluated in four completed Phase 1 trials: NCT00881855, NCT00881426, NCT00881400, and NCT00881153. These trials assessed the relative bioavailability of Cefzil 500 mg cefprozil tablets and Cefzil 250 mg/5 ml cefprozil oral suspension under fed and fasting conditions in healthy volunteers.
Cefprozil is also known by the brand name Cefzil, which appears in the trial titles for the 500 mg tablets and 250 mg/5 ml oral suspension. Additional alternative names include Cefprozil 250 mg/5 ml Oral Suspension and Cefprozil 500 mg Tablets, both associated with Sandoz formulations.
Cefprozil has been studied in Phase 1 clinical trials involving healthy volunteers, with the indications listed as undisclosed. The completed trials focused on demonstrating the relative bioavailability of cefprozil tablets and oral suspension formulations under fed and fasting conditions. No approved indication is specified in the available development information.